Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III Study of Intranasal ARS-1 Epinephrine for Food Allergy–Induced Anaphylactic Symptoms
jRCT2031230143Phase 3Completed
- Sponsor
- ARS Pharmaceuticals
- Start
- Jul 2023
- Modality
- Small Molecules, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of epinephrine in anaphylaxis and food allergy, sponsored by ARS Pharmaceuticals. Primary endpoint: Change in main anaphylactic symptoms at 15 minutes. Started Jul 2023; status: completed.
02
Drugs
epinephrine
03
Conditions
anaphylaxisfood allergy
Beyond the preview
Go deeper on jRCT2031230143.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031230143.